Contrasting Vireo Growth (VREOD) & Its Competitors

Vireo Growth (OTCMKTS:VREOD) is one of 903 public companies in the “Pharmaceuticals” industry, but how does it contrast to its competitors? We will compare Vireo Growth to related businesses based on the strength of its earnings, valuation, analyst recommendations, institutional ownership, profitability, dividends and risk.

Risk & Volatility

Vireo Growth has a beta of 1.78, indicating that its share price is 78% more volatile than the S&P 500. Comparatively, Vireo Growth’s competitors have a beta of -3.18, indicating that their average share price is 418% less volatile than the S&P 500.

Earnings and Valuation

This table compares Vireo Growth and its competitors gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Vireo Growth	$268.77 million	-$68.11 million	-3.02
Vireo Growth Competitors	$4.43 billion	$3.15 billion	547.15

Vireo Growth’s competitors have higher revenue and earnings than Vireo Growth. Vireo Growth is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Insider & Institutional Ownership

32.6% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 3.8% of Vireo Growth shares are owned by insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent recommendations for Vireo Growth and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vireo Growth	1	0	0	0	1.00
Vireo Growth Competitors	7585	13648	25432	998	2.42

As a group, “Pharmaceuticals” companies have a potential upside of 30.14%. Given Vireo Growth’s competitors stronger consensus rating and higher probable upside, analysts clearly believe Vireo Growth has less favorable growth aspects than its competitors.

Profitability

This table compares Vireo Growth and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vireo Growth	-23.37%	-19.76%	-7.15%
Vireo Growth Competitors	-2,299.87%	-222.98%	-17.45%

Summary

Vireo Growth competitors beat Vireo Growth on 9 of the 13 factors compared.

About Vireo Growth

Goodness Growth Holdings, Inc. operates as a cannabis company in the United States. The company cultivates, processes, and distributes medical and adult-use cannabis products. It sells cannabis products through its network of Green Goods and other Goodness Growth branded retail dispensaries and third-party dispensaries in Maryland, Minnesota, and New York. The company was formerly known as Vireo Health International Inc. and changed its name to Goodness Growth Holdings, Inc. in June 2021. Goodness Growth Holdings, Inc. is headquartered in Minneapolis, Minnesota.